StockData

Biofrontera vs Verrica Pharmaceuticals

BFRI and VRCA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BFRI and VRCA compare

Verrica Pharmaceuticals is the larger company, worth 5.9 times as much as Biofrontera ($61.2M against $10.4M).

Biofrontera grew revenue faster over the last twelve months (29.8% versus −25.7% for Verrica Pharmaceuticals).

Biofrontera keeps more of each dollar of sales as profit, with a net margin of −12.7% compared with −189% at Verrica Pharmaceuticals.

Biofrontera scores higher on the StockData Score (9 against 4 for Verrica Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBFRIVRCA
Size and price
Market cap$10.4M$61.2M
Share price$0.700$3.56
Change, 1 year−28.1%−6.8%
Change, 5 years−98.7%−96.9%
Beta (5Y)0.971.08
Employees9276
StockData Score
Total score9 (better)4
Valuation score11
Growth score2 (better)1
Performance score2 (better)1
Health score4 (better)1
Dividend score00
Valuation
P/S0.2× (better)2.7×
FCF yield−53.4%–
Growth
Revenue growth (TTM)29.8% (better)−25.7%
Revenue growth, 5Y average17.2%–
Profitability
Operating margin−14.1% (better)−184%
Net margin−12.7% (better)−189%
FCF margin−11.5%–
Financial health
Interest coverage–−21.9×
Current ratio0.781.66 (better)
Altman Z-score−7.80 (better)−14.33
Piotroski F-score34 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions18.6%27.1%
Held by insiders23.6%–
Insider net buying, 12 months–$211K
Short interest, % of float1.7%–

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.